These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23192888)

  • 41. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deliquescence of pharmaceutical systems.
    Mauer LJ; Taylor LS
    Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Patents of Pharmaceutical Co-Crystals: Product Development on Anti-Cancer Drugs and Beyond.
    Tharik AAMS; Meyyanathan SN
    Recent Pat Anticancer Drug Discov; 2023; 18(3):246-267. PubMed ID: 36100994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthon Approach in Crystal Engineering to Modulate Physicochemical Properties in Organic Salts of Chlorpropamide.
    Menon AM; Sidhartha NN; Shruti I; Suresh A; Meena R; Dikundwar AG; Chopra D
    Mol Pharm; 2024 Jun; 21(6):2894-2907. PubMed ID: 38688017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accelerating proof of concept for small molecule drugs using solid-state chemistry.
    Byrn SR; Zografi G; Chen X
    J Pharm Sci; 2010 Sep; 99(9):3665-75. PubMed ID: 20589946
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications.
    Guo M; Sun X; Chen J; Cai T
    Acta Pharm Sin B; 2021 Aug; 11(8):2537-2564. PubMed ID: 34522597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
    He Y; Ho C; Yang D; Chen J; Orton E
    J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cocrystal dissociation in the presence of water: a general approach for identifying stable cocrystal forms.
    Eddleston MD; Madusanka N; Jones W
    J Pharm Sci; 2014 Sep; 103(9):2865-2870. PubMed ID: 24824298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties.
    Grossjohann C; Serrano DR; Paluch KJ; O'Connell P; Vella-Zarb L; Manesiotis P; Mccabe T; Tajber L; Corrigan OI; Healy AM
    J Pharm Sci; 2015 Apr; 104(4):1385-98. PubMed ID: 25605031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of pharmaceutical cocrystals as intellectual property.
    Trask AV
    Mol Pharm; 2007; 4(3):301-9. PubMed ID: 17477544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advancements in mechanical reduction methods: particulate systems.
    Leleux J; Williams RO
    Drug Dev Ind Pharm; 2014 Mar; 40(3):289-300. PubMed ID: 23988193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eutectics as improved pharmaceutical materials: design, properties and characterization.
    Cherukuvada S; Nangia A
    Chem Commun (Camb); 2014 Jan; 50(8):906-23. PubMed ID: 24322207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.
    Gadade DD; Pekamwar SS
    Adv Pharm Bull; 2016 Dec; 6(4):479-494. PubMed ID: 28101455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.
    Cavanagh KL; Maheshwari C; Rodríguez-Hornedo N
    J Pharm Sci; 2018 Jan; 107(1):113-120. PubMed ID: 29097226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benefits of cocrystallisation in pharmaceutical materials science: an update.
    Friščić T; Jones W
    J Pharm Pharmacol; 2010 Nov; 62(11):1547-59. PubMed ID: 21039540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of co-crystals in pharmaceutical design.
    Steed JW
    Trends Pharmacol Sci; 2013 Mar; 34(3):185-93. PubMed ID: 23347591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?
    Dalpiaz A; Pavan B; Ferretti V
    Drug Discov Today; 2017 Aug; 22(8):1134-1138. PubMed ID: 28130117
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.